toxylact: a04ab56 doxylamine combinations
The first professional lActological database in the word
Doxylamine combinations (ATC A04AB56) are sedating H1‑antihistamines used in fixed combinations mainly for prevention and treatment of nausea and vomiting, including motion sickness and functional gastrointestinal complaints, with additional use as short‑term hypnotics due to their pronounced sedative effect.medpedia.framar
Pharmacological profile
Doxylamine is an ethanolamine‑class
first‑generation H1‑antihistamine
with central and peripheral antihistaminic, anticholinergic
and sedative
properties.medpedia.framar
In A04AB56 products it is combined with other agents (e.g.
vitamins, antacids,
pyridoxine or additional antiemetics) to broaden antiemetic
efficacy and
improve tolerability in gastrointestinal indications. These
combinations are
formulated for oral use, typically as immediate‑release
tablets taken before
travel or at bedtime when nausea is prominent.medpedia.framar
Indications and clinical use in lactation
A04AB56 doxylamine combinations are indicated
for the symptomatic
treatment of nausea and vomiting, particularly
motion‑induced or functional
gastrointestinal complaints, and may be used off‑label as
short‑term sleep aids
because of their sedative action.medpedia.framar
In breastfeeding women, these combinations are considered
only when non‑pharmacological
measures and safer antiemetic alternatives have failed,
since sedation and
anticholinergic effects may occur both in the mother and in
the infant; short
courses at the lowest effective dose and avoidance in
premature or medically
fragile infants are generally advised.medpedia.framar
Contraindications and cautions in breastfeeding
Use of doxylamine combinations is
contraindicated in patients
with known hypersensitivity to doxylamine or any component
of the combination
product.medpedia.framar
In lactating patients, additional caution is required in
mothers with pre‑existing
sedation, sleep apnea, narrow‑angle glaucoma, urinary
retention, severe hepatic
impairment or concomitant use of other CNS depressants,
because doxylamine’s
sedative and anticholinergic profile can be additive and may
increase the risk
of maternal falls, impaired caregiving and potential infant
exposure via breast
milk.medpedia.framar
Adverse effects and toxicological considerations
The most frequent adverse reactions at
therapeutic doses are
drowsiness, asthenia, dizziness, fatigue and impaired
concentration, reflecting
central H1‑receptor blockade and anticholinergic burden.medpedia.framar
In breastfed infants, potential toxicological‑lactological
concerns include
excessive somnolence, poor suck, irritability or paradoxical
excitation, and
rarely respiratory depression if exposure is high or
combined with other
sedatives, so monitoring of infant behaviour and feeding is
recommended when
the mother receives A04AB56 combinations.medpedia.framar
Dosage, administration and regulatory status
Doxylamine combinations in ATC A04AB56 are
administered orally as
tablets, usually once or several times daily depending on
the specific
combination and indication, and should be taken with water;
timing before
travel or meals is individualised.medpedia.framar
Access to these products is generally restricted to
prescription‑only status,
reflecting the need for medical evaluation of underlying
causes of nausea and
vomiting, assessment of maternal and infant risk in
lactation, and structured
follow‑up for sedative and anticholinergic adverse effects.medpedia.framar



